跳至主要内容
临床试验/NL-OMON39562
NL-OMON39562
已完成
不适用

DUrable Polymer-based STent CHallenge of Promus ElemEnt versus ReSolute Integrity (DUTCH PEERS): Randomized Multicenter Trial in All-Comers Population Treated Within Eastern NeThErlands-2 (TWENTE-2) - DUTCH PEERS (TWENTE-2)

Medisch Spectrum Twente0 个研究点目标入组 1,788 人待定

概览

阶段
不适用
干预措施
未指定
疾病 / 适应症
arteriosclerose
发起方
Medisch Spectrum Twente
入组人数
1788
状态
已完成
最后更新
去年

概览

简要总结

暂无简介。

注册库
who.int
开始日期
待定
结束日期
待定
最后更新
去年
研究类型
Observational non invasive

研究者

入排标准

入选标准

  • Minimum age of 18 years \* Coronary artery disease and lesion(s) eligable for treatment with drug eluting stents according to clinical guidelines and/or the operators\* judgement \* Patient is willing and able to cooperate with study procedures and required follow\-up visits; and patient has been informed and agrees on the participation by signing an EC approved written informed consent.

排除标准

  • Participation in another randomized drug or device study before reaching primary endpoint \* Planned surgery within 6 months of PCI unless dual antiplatelet therapy is maintained throughout the peri\-surgical period \* Intolerance to a P2Y12 receptor antagonist that results in the patient\*s inability to adhere to dual\-antiplatelet therapy, or intolerance to aspirin, heparin, or components of the two DES examined \* Known pregnancy \* Life expectancy of less than 1 year

结局指标

主要结局

未指定

相似试验